An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 31 Aug 2018 Biomarkers information updated
- 28 Mar 2017 Status changed from active, no longer recruiting to completed.
- 12 May 2016 Status changed from recruiting to active, no longer recruiting.